explore -WSS

explore

author：knowledge 2025-10-02 22:40:50 - browse：6

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： ALS advocates say criticism of new drugs misses bigger picture

WSS

Bacterial infection may be ‘key event’ in endometriosis, study says

What drug price negotiations mean for Medicare Part D

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

AstraZeneca chief proposes a novel edit to the drug pricing bill

Community addresses injustice for Long Island mothers

New case study details death in closely watched Alzhiemer's trial

hotspot

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Crinetics acromegaly drug succeeds in late

State Dept. review finds Biden bears some blame for Afghanistan failures

Amazon on where the company's health care bets are headed next

United colonoscopy coverage change 'may cost lives,' doctors say

Why is France rioting? What to know about the fatal police shooting of Nahel M

ChatGPT in medicine: STAT answers readers' burning questions

Illumina names Agilent executive as new CEO

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Biogen's messy board & Laronde's data problem

entertainment

Bacterial infection may be ‘key event’ in endometriosis, study says

Australia's humpback populations rebound raising hopes of marine scientists

What drug price negotiations mean for Medicare Part D

The 10 drugs up first for Medicare price negotiation

These geoengineering technologies could help combat the climate crisis, scientists say

How generative AI is inspiring dreams of a health data revolution

hotspot

Wikipedia

explore

leisure time